Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May-Jun;41(3):218-224.
doi: 10.1590/1516-4446-2017-0021. Epub 2018 Nov 8.

Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer's disease in Brazil

Luciana R da Silva  1 , Cid M M Vianna  1 , Gabriela B G Mosegui  2 , Antônio A F Peregrino  3 , Valeska Marinho  4 , Jerson Laks  4   5
Affiliations

Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer's disease in Brazil

Luciana R da Silva et al. Braz J Psychiatry. 2019 May-Jun.

Abstract

Objective: To perform a cost-effectiveness analysis of donepezil and rivastigmine therapy for mild and moderate Alzheimer's disease (AD) from the perspective of the Brazilian Unified Health System.

Method: A hypothetical cohort of 1,000 individuals of both sexes, aged >65 years, and diagnosed with AD was simulated using a Markov model. The time horizon was 10 years, with 1-year cycles. A deterministic and probabilistic sensitivity analysis was performed.

Results: For mild AD, the study showed an increase in quality-adjusted life years (QALYs) of 0.61 QALY/21,907.38 Brazilian reais (BRL) for patients treated with donepezil and 0.58 QALY/BRL 24,683.33 for patients treated with rivastigmine. In the moderate AD group, QALY increases of 0.05/BRL 27,414.96 were observed for patients treated with donepezil and 0.06/BRL 34,222.96 for patients treated with rivastigmine.

Conclusions: The findings of this study contradict the standard of care for mild and moderate AD in Brazil, which is based on rivastigmine. A pharmacological treatment option based on current Brazilian clinical practice guidelines for AD suggests that rivastigmine is less cost-effective (0.39 QALY/BRL 32,685.77) than donepezil. Probabilistic analysis indicates that donepezil is the most cost-effective treatment for mild and moderate AD.

PubMed Disclaimer

Conflict of interest statement

VM has received grants from Novartis, Wyeth, EMS, Janssen-Cilag, Apsen Farmacê utica, Aché, Lundbeck, Lilly, moksha8, and Servier. JL has received grants from Novartis, Wyeth, EMS, Janssen-Cilag, Apsen Farmacêutica, Aché, Lundbeck, Lilly, moksha8, and Servier. The other authors report no conflicts of interest.

Figures

Figure 1
Figure 1. Schematic representation of the disease stages of the simulation model. AD = Alzheimer’s disease.
Figure 2
Figure 2. Monte Carlo cost-effectiveness analysis of donepezil vs.rivastigmine. WTP = willingness to pay.
See this image and copyright information in PMC

References

    1. Qiu C, Kivipelto M, Von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11:111–28. - PMC - PubMed
    1. World Health Organization/Alzheimer’s Disease International (WHO/ADI) Dementia: a public health priority, [Internet] 2012. [cited 2018 May 23] www.who.int/mental_health/publications/dementia_report_2012/en/
    1. Grinberg LT, Nitrini R, Suemoto CK, Lucena Ferretti-Rebustini RE, Leite RE, Farfel JM, et al. Prevalence of dementia subtypes in a developing country: a clinicopathological study. Clinics (São Paulo) 2013;68:1140–5. - PMC - PubMed
    1. Nitrini R, Bottino CM, Albala C, Custodio Capuñay NS, Ketznoian C, Libre Rodriguez JJ, et al. Prevalence of dementia in Latin America: a collaborative study of population-based cohorts. Int Psychogeriatr. 2009;21:622–30. - PMC - PubMed
    1. Bottino CM, Laks J, Blay SL. Demência e transtornos cognitivos em idosos. In: Machado JCB, editor. Diagnóstico clínico na doença de Alzheimer. Rio de Janeiro: Guanabara Koogan; 2006. pp. 173–6.